Resource Summary Report

Generated by RRID on Sep 7, 2026

Myc-CaP

RRID:CVCL_J703
Type: Cell Line

Proper Citation

ATCC Cat# CRL-3255, RRID:CVCL_J703

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_J703

Proper Citation: ATCC Cat# CRL-3255, RRID:CVCL_J703

Description: Cell line Myc-CaP is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Carcinoma of the mouse prostate gland

Defining Citation: PMID:16357166

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Myc-CaP

Cross References: BTO:BTO_0005126, ATCC:CRL-3255, Wikidata:Q54907155

ID: CVCL_J703

Vendor: ATCC

Catalog Number: CRL-3255

Record Creation Time: 20220427T220829+0000

Record Last Update: 20260905T181225+0000

Ratings and Alerts

No rating or validation information has been found for Myc-CaP.

No alerts have been found for Myc-CaP.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Murphy KC, et al. (2025) MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer research, 85(22), 4359.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science advances, 11(29), eadw5228.

Kirthika P, et al. (2025) Off-pore Nucleoporin sPOM121 Transcriptionally Propels ?-Catenin-driven Tumor Progression and Immune Escape in Prostate Cancer. Cancer discovery, 15(11), 2374.

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. Cell reports. Medicine, 6(1), 101890.

Classon J, et al. (2025) Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models. Molecular oncology.

Hirani R, et al. (2025) BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. Cell reports, 44(6), 115779.

Boufaied N, et al. (2024) Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. Cancer research, 84(11), 1834.

Van Espen B, et al. (2024) RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic Potential. Molecular cancer research : MCR, 22(1), 41.

Lim RJ, et al. (2024) CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell reports. Medicine, 5(4), 101479.

Santasusagna S, et al. (2023) Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Cancer discovery, 13(12), 2584.

Wang H, et al. (2023) Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer cell, 41(7), 1345.

Wang H, et al. (2022) ?-Tocotrienol is the Most Potent Vitamin E Form in Inhibiting Prostate Cancer Cell Growth and Inhibits Prostate Carcinogenesis in Ptenp-/- Mice. Cancer prevention research (Philadelphia, Pa.), 15(4), 233.

Cid-Diaz T, et al. (2022) Air-liquid organotypic assays to investigate cellular crosstalk in the tumor microenvironment of cancer cells. STAR protocols, 3(3), 101635.

Ganaie AA, et al. (2020) Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. Molecular cancer therapeutics, 19(12), 2598.

Han H, et al. (2019) Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer cell, 36(5), 483.

Jiao S, et al. (2019) Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell, 179(5), 1177.

Su W, et al. (2019) The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer cell, 36(2), 139.

Chen JC, et al. (2018) IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy. Cell systems, 7(1), 92.